Literature DB >> 8444079

Reduced production of immunoreactive interleukin-1 by peripheral blood monocytes of patients with acute and chronic viral hepatitis.

C Müller1, P Knoflach, C C Zielinski.   

Abstract

The in vitro production of interleukin-1 beta by peripheral blood monocytes derived from patients with various liver diseases was studied. An impaired production of immunoreactive interleukin-1 (IL-1) (mean +/- SEM) by monocytes stimulated with an optimal dose (100 ng/ml) of lipopolysaccharide was observed in patients with chronic hepatitis B (N = 13; 32 +/- 6 pg/ml) or chronic hepatitis C (N = 13; 61 +/- 12 pg/ml) as compared to those of healthy control individuals (N = 35; 166 +/- 24 pg/ml; P = 0.0003 and P = 0.015, respectively), whereas an unaltered IL-1 production was seen in patients with alcoholic cirrhosis (N = 23; 125 +/- 28 pg/ml) and primary biliary cirrhosis (N = 6; 111 +/- 33 pg/ml). Similar to the situation seen in chronic viral hepatitis, lipopolysaccharide-stimulated monocytes from patients with acute hepatitis also showed a decreased IL-1 production in the first week after onset of jaundice (N = 17; 55 +/- 20 pg/ml; P = 0.001) and a return to normal in the second and third week. An impaired production of IL-1 in chronic as well as acute viral hepatitis is a further example of the known disturbed immunoregulation in this disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8444079     DOI: 10.1007/bf01316502

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  34 in total

1.  In vitro hepatitis B virus infection of human bone marrow cells.

Authors:  J B Zeldis; H Mugishima; H N Steinberg; E Nir; R P Gale
Journal:  J Clin Invest       Date:  1986-08       Impact factor: 14.808

2.  Failure of exogenous interleukin 1 and interleukin 2 to correct decreased lymphocyte transformation in chronic hepatitis B virus carriers.

Authors:  C Anastassakos; G J Alexander; R A Wolstencroft; D C Dumonde; A L Eddleston; R Williams
Journal:  Clin Exp Immunol       Date:  1987-04       Impact factor: 4.330

Review 3.  Interleukin-1.

Authors:  C A Dinarello
Journal:  Dig Dis Sci       Date:  1988-03       Impact factor: 3.199

Review 4.  Interleukin-1.

Authors:  C A Dinarello
Journal:  Rev Infect Dis       Date:  1984 Jan-Feb

5.  Hepatitis B virus infection in cultured human lymphoblastoid cells.

Authors:  J L Romet-Lemonne; M F McLane; E Elfassi; W A Haseltine; J Azocar; M Essex
Journal:  Science       Date:  1983-08-12       Impact factor: 47.728

6.  Inhibition of human hemopoiesis by non-A, non-B hepatitis virus.

Authors:  J B Zeldis; P J Boender; J A Hellings; H Steinberg
Journal:  J Med Virol       Date:  1989-01       Impact factor: 2.327

7.  Natural killer activity in patients with biopsy-proven liver disease.

Authors:  S Serdengecti; D B Jones; G Holdstock; R Wright
Journal:  Clin Exp Immunol       Date:  1981-08       Impact factor: 4.330

8.  Interleukin-1 and interleukin-2 activity in chronic hepatitis B virus infection.

Authors:  C Anastassakos; G J Alexander; R A Wolstencroft; J A Avery; B C Portmann; G S Panayi; D C Dumonde; A L Eddleston; R Williams
Journal:  Gastroenterology       Date:  1988-04       Impact factor: 22.682

9.  Impaired concanavalin A-inducible suppressor T-cell activity in active alcoholic liver disease.

Authors:  H Kawanishi; H Tavassolie; R P MacDermott; J N Sheagren
Journal:  Gastroenterology       Date:  1981-03       Impact factor: 22.682

10.  Tumor necrosis factor alpha/cachectin is a growth factor for thymocytes. Synergistic interactions with other cytokines.

Authors:  G E Ranges; A Zlotnik; T Espevik; C A Dinarello; A Cerami; M A Palladino
Journal:  J Exp Med       Date:  1988-04-01       Impact factor: 14.307

View more
  6 in total

1.  Monokine production by peripheral whole blood in chronic hepatitis C patients treated with interferon.

Authors:  Y Itoh; T Okanoue; S Sakamoto; K Nishioji; K Yasui; M Sakamoto; K Kashima
Journal:  Dig Dis Sci       Date:  1995-11       Impact factor: 3.199

2.  Hepatitis A virus suppresses monocyte-to-macrophage maturation in vitro.

Authors:  Sabina Wünschmann; Britta Becker; Angelika Vallbracht
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

3.  T cell responses to tuberculin purified protein derivative in primary biliary cirrhosis: evidence for defective T cell function.

Authors:  D E Jones; J M Palmer; M P Leon; S J Yeaman; M F Bassendine; A G Diamond
Journal:  Gut       Date:  1997-02       Impact factor: 23.059

4.  Interleukin-1 inhibits hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway.

Authors:  Haizhen Zhu; Chen Liu
Journal:  J Virol       Date:  2003-05       Impact factor: 5.103

5.  IL-1 beta and TNF-alpha produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C.

Authors:  Y Kishihara; J Hayashi; E Yoshimura; K Yamaji; K Nakashima; S Kashiwagi
Journal:  Dig Dis Sci       Date:  1996-02       Impact factor: 3.199

6.  Serum levels of soluble immune factors and pathogenesis of chronic hepatitis C, and their relation to therapeutic response to interferon-alpha.

Authors:  J A Quiroga; J Martin; M Pardo; V Carreño
Journal:  Dig Dis Sci       Date:  1994-11       Impact factor: 3.199

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.